0001104659-23-122819.txt : 20231201 0001104659-23-122819.hdr.sgml : 20231201 20231201160126 ACCESSION NUMBER: 0001104659-23-122819 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231130 FILED AS OF DATE: 20231201 DATE AS OF CHANGE: 20231201 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Islam Saqib CENTRAL INDEX KEY: 0001575408 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39044 FILM NUMBER: 231459448 MAIL ADDRESS: STREET 1: ALEXION PHARMACEUTICALS STREET 2: 352 KNOTTER DRIVE CITY: CHESHIRE STATE: CT ZIP: 06410 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SpringWorks Therapeutics, Inc. CENTRAL INDEX KEY: 0001773427 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 BUSINESS PHONE: 203-883-9490 MAIL ADDRESS: STREET 1: 100 WASHINGTON BOULEVARD CITY: STAMFORD STATE: CT ZIP: 06902 4 1 tm2331963-1_4seq1.xml OWNERSHIP DOCUMENT X0508 4 2023-11-30 0 0001773427 SpringWorks Therapeutics, Inc. SWTX 0001575408 Islam Saqib C/O SPRINGWORKS THERAPEUTICS, INC. 100 WASHINGTON BLVD. STAMFORD CT 06902 1 1 0 0 Chief Executive Officer 0 Common Stock 2023-11-30 4 A 0 199053 0.00 A 199053 D This transaction represents the grant of performance restricted stock units ("PSUs"). Each PSU represents a contingent right to receive one share of the Issuer's Common Stock upon vesting. The PSUs were originally granted on January 5, 2023, subject to the achievement of a certain performance based milestone within four years from the grant date, which milestone was achieved as a result of approval by the U.S. Food and Drug Administration of the Issuer's lead product candidate, Ogsiveo, for the treatment of desmoid tumors. 66,351 PSUs shall vest on the date that is 15 months following November 30, 2023, another 66,351 PSUs shall vest on the date that is 27 months following November 30, 2023 and the remaining 66,351 PSUs shall vest on the date that is the later of (i) 39 months following November 30, 2023 or (ii) the Measurement Period End Date (as defined below), subject to continued service to the Issuer by the Reporting Person as of each such vesting date; provided that, such remaining 66,351 PSUs shall be subject to an upwards or downwards adjustment described in the PSU award agreement. As used herein, "Measurement Period End Date" means the first to occur of (i) December 31, 2026 or (ii) the date of consummation of a Sale Event (as defined in Issuer's 2019 Stock Option and Equity Incentive Plan). /s/ Francis I. Perier, Jr. as Attorney-in Fact 2023-12-01